Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C9H8NO3.H4N |
| Molecular Weight | 196.2032 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[NH4+].[O-]C(=O)CNC(=O)C1=CC=CC=C1
InChI
InChIKey=RXBWNIYFOFYPJR-UHFFFAOYSA-N
InChI=1S/C9H9NO3.H3N/c11-8(12)6-10-9(13)7-4-2-1-3-5-7;/h1-5H,6H2,(H,10,13)(H,11,12);1H3
| Molecular Formula | H3N |
| Molecular Weight | 17.0305 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C9H9NO3 |
| Molecular Weight | 179.1727 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/19891605 and https://www.medicines.org.uk/emc/medicine/7597
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/19891605 and https://www.medicines.org.uk/emc/medicine/7597
Hippuric Acid is an acyl glycine produced by the conjugation of benzoic acid and glycine, found as a normal component in urine as a metabolite of aromatic compounds from food. Increased urine hippuric acid content may have antibacterial effects. Hippuric Acid is used therapeutically in the form of its salts (hippurates of calcium and ammonium). It is an ingredient of FDA-approved drug Hiprex (methenamine hippurate tablets USP). Each yellow capsule-shaped tablet of Hiprex contains 1 g Methenamine Hippurate which is the Hippuric Acid Salt of Methenamine (hexamethylene tetramine). The tablet also contains inactive ingredients. Hiprex (methenamine hippurate tablets USP) has antibacterial activity because the methenamine component is hydrolyzed to formaldehyde in acid urine. Hippuric acid has some antibacterial activity and also acts to keep the urine acid. The drug is generally active against E. coli, enterococci and staphylococci. Enterobacter aerogenes is generally resistant. The urine must be kept sufficiently acid for urea-splitting organisms such as Proteus and Pseudomonas to be inhibited. Hiprex is indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1641347 |
20.0 µM [IC50] | ||
Target ID: CHEMBL1641348 |
30.8 µM [Ki] | ||
Target ID: Bacterial growth |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | HIPREX Approved UseHIPREX is indicated for prophylactic or suppressive treatment of frequently recurring urinary
tract infections when long-term therapy is considered necessary. This drug should only be used
after eradication of the infection by other appropriate antimicrobial agents. Launch Date1976 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Secretory activity and aryl acid content of serum, urine, and cerebrospinal fluid in normal and uremic man. | 1975 May |
|
| Assays for angiotensin converting enzyme inhibitory activity. | 2001 Apr 1 |
|
| Hippurate participates in the correction of metabolic acidosis. | 2001 Feb |
|
| Protein-bound uremic solutes: the forgotten toxins. | 2001 Feb |
|
| DNA damage of lymphocytes in experimental chronic renal failure: beneficial effects of losartan. | 2001 Feb |
|
| Modified method for determination of hippuric acid and methylhippuric acid in urine by gas chromatography. | 2001 Feb 10 |
|
| Classification of Brachyspira spp. isolated from Swedish dogs. | 2001 Jun |
|
| Hepatic uptake and metabolism of benzoate: a multiple indicator dilution, perfused rat liver study. | 2001 Jun |
|
| Hippuric acid test using 13C-labelling and NMR spectroscopy. | 2001 Mar |
|
| Oxidation of albumin is enhanced in the presence of uremic toxins. | 2001 May-Jul |
|
| Uremic sera contain inhibitors that block digitoxin-valproic acid interaction. | 2001 Oct |
|
| Synthesis of some new quinoline derivatives: new routes to synthesize polysubstituted 2(1H)-quinolone derivatives. | 2001 Sep-Oct |
|
| Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. | 2002 Aug |
|
| Metabolite ratio of toluene-exposed rotogravure printing plant workers reflects individual mutagenic risk by sister chromatid exchanges. | 2002 Aug 26 |
|
| Uraemic toxins induce proximal tubular injury via organic anion transporter 1-mediated uptake. | 2002 Jan |
|
| Improved method for direct high-performance liquid chromatography assay of angiotensin-converting enzyme-catalyzed reactions. | 2002 Mar 15 |
|
| Cytogenetic analysis of buccal cells from shoe-workers and pathology and anatomy laboratory workers exposed to n-hexane, toluene, methyl ethyl ketone and formaldehyde. | 2002 Mar-Apr |
|
| Analytical reproducibility in (1)H NMR-based metabonomic urinalysis. | 2002 Nov |
|
| Effect of intestinal microflora on the urinary metabolic profile of rats: a (1)H-nuclear magnetic resonance spectroscopy study. | 2002 Sep |
|
| Hippuric acid and methyl hippuric acid in rat hair: possible monitoring of xylene and toluene exposure. | 2003 Apr 23 |
|
| Determination of urinary hippuric acid by micellar electrokinetic capillary chromatography. | 2003 Aug 15 |
|
| Kinetic study of angiotensin converting enzyme activity by capillary electrophoresis after in-line reaction at the capillary inlet. | 2003 Feb 7 |
|
| Glycine conjugation of para-aminobenzoic acid (PABA): a pilot study of a novel prognostic test in acute liver failure in children. | 2003 Jan |
|
| Carboxymethyl benzylamide dextran inhibits angiogenesis and growth of VEGF-overexpressing human epidermoid carcinoma xenograft in nude mice. | 2003 Jul 7 |
Sample Use Guides
1 tablet (1.0 g) twice daily (morning and night) for adults and pediatric patients over 12 years of age. 1/2 to 1 tablet (0.5 to 1.0 g) twice daily (morning and night) for pediatric patients 6 to 12 years of age. Since the antibacterial activity of Hiprex is greater in acid urine, restriction of alkalinizing foods and medications is desirable.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 04:02:23 GMT 2023
by
admin
on
Sat Dec 16 04:02:23 GMT 2023
|
| Record UNII |
04ZTA613HX
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
208-547-9
Created by
admin on Sat Dec 16 04:02:23 GMT 2023 , Edited by admin on Sat Dec 16 04:02:23 GMT 2023
|
PRIMARY | |||
|
04ZTA613HX
Created by
admin on Sat Dec 16 04:02:23 GMT 2023 , Edited by admin on Sat Dec 16 04:02:23 GMT 2023
|
PRIMARY | |||
|
532-93-4
Created by
admin on Sat Dec 16 04:02:23 GMT 2023 , Edited by admin on Sat Dec 16 04:02:23 GMT 2023
|
PRIMARY | |||
|
m6023
Created by
admin on Sat Dec 16 04:02:23 GMT 2023 , Edited by admin on Sat Dec 16 04:02:23 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID90201261
Created by
admin on Sat Dec 16 04:02:23 GMT 2023 , Edited by admin on Sat Dec 16 04:02:23 GMT 2023
|
PRIMARY | |||
|
71092
Created by
admin on Sat Dec 16 04:02:23 GMT 2023 , Edited by admin on Sat Dec 16 04:02:23 GMT 2023
|
PRIMARY |